Skip to main content

Anteris Technologies Global Corp.

corporate_fare Company Profile

Anteris Technologies Global Corp.

AVR·NASDAQ·Industrial Applications And Services·CIK 0002011514

Anteris Technologies Global Corp. is a structural heart company focused on cardiac care through science-driven advancements to restore heart valve patients to healthy function. Its lead product, the DurAVR® THV System, is designed to treat aortic stenosis, a potentially life-threatening narrowing of the aortic valve. The balloon-expandable DurAVR® THV is described as the first biomimetic valve, shaped to mimic the performance of a healthy human aortic valve and aiming to replicate normal aortic blood flow. The DurAVR® THV System consists of a single-piece, biomimetic valve made with the company's proprietary ADAPT® tissue-enhancing technology and deployed with its balloon-expandable ComASUR® Delivery System. ADAPT® is a proprietary anti-calcification tissue shaping technology designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. According to the cited publication by William Neethling et al., the patented ADAPT® tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure and has been distributed for use in over 55,000 patients globally in other indications. The ComASUR® Delivery System, developed in consultation with physicians, is designed to provide precise alignment with the heart's native commissures for accurate placement of the DurAVR® THV. As of December 2025, more than 130 patients have been implanted with the DurAVR® THV worldwide. Aortic stenosis is one of the most common and serious valvular heart diseases; it is fatal in approximately 50% of patients if left untreated after two years, and no pharmacotherapy is available to treat it.

Anteris Technologies Global Corp. (NASDAQ:AVR) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 33 items for AVR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Anteris Technologies Registers 9.1M Shares for Resale, Creating Significant Potential Dilution
  • Anteris Reports 2025 Financial Results and Provides Corporate Update
  • Anteris Technologies Secures $320M Capital, Resolves Going Concern, and Confirms Medtronic Strategic Partnership
  • 10% Owner L1 Capital Acquires $35.3M in Anteris Technologies Shares Amidst Recent Capital Raise
  • Medtronic Discloses 16.2% Strategic Stake in Anteris Technologies, Securing Board Observer & Key Rights

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.91M
Net Income
-$94.14M
Diluted EPS
-$2.55
Op. Cash Flow
-$77.8M
Free Cash Flow
-$79.76M
Gross Profit
$1.34M
Operating Income
-$93.89M
Cash & Equivalents
$12.58M
Debt / Equity
0.00×
Net Margin
-49.21×
Shares Outstanding
41.58M sh
Source: 10-K · filed 2026-02-26 · accession 0001140361-26-006977
$5.09 +2.00% today
52-week range · as of 2026-11-10 $3.3 – $11.05
Market cap
$486.49M
Volume
1.5M (1.1× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVR - Filings & News (Page 2)

AVR
Mar 18, 2026, 8:46 AM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $5.98
Real-time Price: $5.09 info
Change: -$0.890 (-15%) info
Market Cap: $486.492M info
AVR
Feb 26, 2026, 6:00 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.22
Real-time Price: $5.09 info
Change: -$1.13 (-18%) info
Market Cap: $486.492M info
AVR
Feb 26, 2026, 4:07 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $6.22
Real-time Price: $5.09 info
Change: -$1.13 (-18%) info
Market Cap: $486.492M info
AVR
Feb 09, 2026, 8:49 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $5.47
Real-time Price: $5.09 info
Change: -$0.3843 (-7%) info
Market Cap: $486.492M info
AVR
Jan 29, 2026, 5:06 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $6.25
Real-time Price: $5.09 info
Change: -$1.16 (-19%) info
Market Cap: $486.492M info
AVR
Jan 22, 2026, 6:57 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $5.09 info
Change: -$1.41 (-22%) info
Market Cap: $486.492M info
AVR
Jan 22, 2026, 5:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.50
Real-time Price: $5.09 info
Change: -$1.41 (-22%) info
Market Cap: $486.492M info
AVR
Jan 22, 2026, 6:18 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.95
Real-time Price: $5.09 info
Change: -$0.860 (-14%) info
Market Cap: $486.492M info
AVR
Jan 21, 2026, 9:57 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.95
Real-time Price: $5.09 info
Change: -$0.860 (-14%) info
Market Cap: $486.492M info
AVR
Jan 21, 2026, 6:00 AM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $6.65
Real-time Price: $5.09 info
Change: -$1.56 (-23%) info
Market Cap: $486.492M info
AVR
Jan 20, 2026, 4:18 PM EST
Filing Type: FWP
Importance Score:
9
Price at Filing: $6.18
Real-time Price: $5.09 info
Change: -$1.09 (-18%) info
Market Cap: $486.492M info
AVR
Jan 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $5.09 info
Change: -$1.11 (-18%) info
Market Cap: $486.492M info
AVR
Jan 02, 2026, 5:20 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $5.09 info
Change: +$0.080 (+2%) info
Market Cap: $486.492M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets